Hervolution Therapeutics
InProTher develops BreakImmune, a cancer immunotherapy that targets HERVs (expressed in breast, prostate, ovarian, and pancreatic malignancies). HERVs help the immune system eliminate tumor cells. Learn more
Launch date
Employees
Market cap
-
Enterprise valuation
$26—40m (Dealroom.co estimates May 2023.)
Company register number 33968426
Copenhagen Capital Region of Denmark (HQ)
Financials
Estimates*
| EUR | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Profit | <1m | <1m | (<1m) | (<1m) | (<1m) | (<1m) | (1.5m) |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
€200k | Grant | ||
* | €2.5m | Grant | |
* | €6.0m | Seed | |
| Total Funding | $9.6m | ||
Related Content
Recent News about Hervolution Therapeutics
EditMore about Hervolution Therapeutics
EditOperator of a biotechnology company intended to treat cancer by targeting tumor viruses within the human genome. The company offers broad and curative cancer therapy in combination with immune checkpoint inhibitors, enabling medical researchers to easily find treatment for cancer using adaptive immune therapy.
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.